Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

6.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.0K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

248
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
248

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A real-world feasibility evaluation of LLM-based clinical prediction: emergency department return visit admission across two academic medical centers.

Research square·2026
Same author

Outcomes of 72-hour emergency department return visits requiring hospital admission in older adults: a nationally representative analysis.

BMC geriatrics·2026
Same author

Glymphatic dysfunction is unlikely to cause idiopathic intracranial hypertension.

Headache·2026
Same author

Temporal Evolution of ARIA After Lecanemab Interruption: A Longitudinal Volumetric MRI Study.

AJNR. American journal of neuroradiology·2026
Same author

The Glymphatic System in Idiopathic Intracranial Hypertension.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2026
Same author

Relationship of Inferior Frontal Sulcal Hyperintensities with Amyloid-Related Imaging Abnormalities.

AJNR. American journal of neuroradiology·2026

Related Experiment Video

Updated: Sep 23, 2025

In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats
09:36

In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats

Published on: March 23, 2022

2.3K

Statistical Parametric Mapping in Amyloid Positron Emission Tomography.

Natasha M Smith1, Jeremy N Ford2,3, Arsalan Haghdel1

  • 1Department of Radiology and MD Program, Weill Cornell Medicine, New York City, NY, United States.

Frontiers in Aging Neuroscience
|May 13, 2022
PubMed
Summary
This summary is machine-generated.

Statistical Parametric Mapping (SPM) offers a more sensitive quantitative approach for assessing amyloid burden in Alzheimer's disease (AD) compared to qualitative methods. This technique improves diagnostic performance and correlates better with cerebrospinal fluid biomarkers, aiding in treatment response assessment.

Keywords:
Alzheimer’s diseasePETSPMamyloiddementia

More Related Videos

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET
09:03

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET

Published on: October 22, 2019

10.3K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

376

Related Experiment Videos

Last Updated: Sep 23, 2025

In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats
09:36

In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats

Published on: March 23, 2022

2.3K
Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET
09:03

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET

Published on: October 22, 2019

10.3K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

376

Area of Science:

  • Neuroimaging
  • Biomarker Discovery
  • Alzheimer's Disease Diagnostics

Background:

  • Alzheimer's disease (AD) lacks effective treatments, with emerging therapies targeting amyloid-β (Aβ) clearance.
  • Quantitative assessment of amyloid burden is crucial for disease progression and treatment response but is not routinely performed.
  • Statistical Parametric Mapping (SPM) shows potential for improved amyloid PET quantification, yet its utility and optimal database construction for AD diagnosis are under investigation.

Purpose of the Study:

  • To evaluate the utility of SPM in quantifying amyloid burden using a "true normal" database for Alzheimer's disease (AD) diagnosis.
  • To compare the diagnostic performance of SPM against qualitatively rated [11C]-PiB PET and cerebrospinal fluid (CSF) biomarkers.
  • To determine if regional SPM z-scores predict CSF Aβ42 levels, indicating early AD-related brain changes.

Main Methods:

  • A database of 34 cognitively normal, non-APOE ε4 carriers with negative CSF AD biomarkers was created for SPM analysis.
  • SPM was used to analyze amyloid PET scans from 115 cognitively normal subjects with varying AD risk factors.
  • Agreement between SPM, qualitatively rated [11C]-PiB PET (QR-PiB), and CSF biomarkers was assessed using Fisher's exact test and kappa coefficient. Logistic regression identified predictors of CSF Aβ42 levels.

Main Results:

  • SPM identified significantly more positive amyloid scans (19.1%) than QR-PiB PET (9.6%), suggesting higher sensitivity.
  • SPM showed a stronger correlation with CSF Aβ42 levels (kappa 0.13) compared to QR-PiB PET (kappa 0.06).
  • Regional z-scores in the precuneus, anterior cingulate, and posterior cingulate were predictive of CSF Aβ42 levels (p < 0.05).

Conclusions:

  • SPM, utilizing a "true normal" database, enhances diagnostic performance for Alzheimer's disease (AD) through quantitative amyloid burden assessment.
  • The quantitative nature of SPM offers improved sensitivity and correlation with CSF biomarkers over qualitative interpretations.
  • SPM's quantitative approach is vital for monitoring disease progression and treatment response, particularly with the advent of disease-modifying therapies.